IGF1R and Ewing sarcoma: Such a biomarker does not yet exist for IGF-1R directed therapy in ES, although recent studies have suggested that differential expression and activation of the insulin receptor and nuclear localization of phosphorylated IGF-1R may be useful predictors of treatment response (Garofalo et al., 2011; Asmane et al., 2012).